Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 3269-3274

  Zolota, Vassiliki ^a   Gerokosta, Artemis ^a   Melachrinou, Maria ^a   Kominea, Athina ^b   Aletra, Christina ^c   Scopa, Chrisoula D ^a,d  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b Aegion General Hospital   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^d NONE   (Greece)

Author keywords

Angiogenesis; bcl 2; Breast; Ductal carcinoma in situ; Ki 67; p53

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; BREAST DUCT; CANCER GROWTH; CARCINOMA IN SITU; CELL PROLIFERATION; COMEDO; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033404027     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lagios MD: Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 70: 853-871, 1990.
2. Bellamy CO, Mc Donald C, Salter DM, Chetty U, Anderson TJ: Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 24: 16-23, 1943.
3. Page DL, Anderson TJ, Rogers LW: Carcinoma in situ (CIS). In: Diagnostic Histopathology of the Breast (Page DL, ed). Edinburgh, Churchill Livingstone, 1987, pp157-192.
4. Holland R, Peterse JL, Millis RR et al: Prognostic classification of breast ductal carcinoma in situ. Semin Diagn Pathol 11: 167-180, 1994.
5. Silverstein MJ, Poller DN, Waisman JR et al: Prognostic classification of breast ductal carcinoma in situ. Lancet 345: 1154-1157, 1995.
6. Zafrani B, Leroyer A, Fourquet A, et al: Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1: 208-214, 1994.
7. Smith MK, Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804, 1994.
8. Chodak GW, Hospelhorn V, Gittes R, Folkman J: Angiogenic activity as a marker of neoplastic and pre-neoplastic lesions of the human bladder. Ann Surg 192: 762-771, 1981.
9. Guidi AJ, Fischer L, Harris JR, Schnitt SJ: Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86: 614-619, 1994.
10. Gimbrone MJ, Gullino PM: Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 56: 305-318, 1976.
11. Folkman J, Hochberg M: Self-regulation of growth in three dimensions. J Exp Med 138: 745-753, 1973.
12. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
13. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metatasis. Biochim Biophys Acta 1032: 89-118, 1990.
14. Weidner N, Simple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
15. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
16. Karaiossifidi H, Kouri E, Arvaniti H, Sfikas K, Vasilaros S: Tumor angiogenesis in node-negative breast cancer: Relationship with relapse free survival. Anticancer Res 16: 4001-4002, 1996.
17. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 1047-1054, 1991.
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science 253: 49-53, 1991.
19. Barbareschi M, Leonardi E, Mauri FA, et al: p53 and c-erbB-2 expression in breast carcinoma: An immunohistochemical study with correlations to receptor status, proliferation markers, and clinical stage in human breast carcinoma. Am J Clin Pathol 98: 408-418, 1992.
20. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855, 1992.
21. Silvestrini R, Benini E, Daidone MG et al: p53 as an independent prognostic marker in lymph node-negative cancer patients. J Natl Cancer Inst 85: 965-970, 1993.
22. Wang Y, Szekely L, Okan I, Klein G, Wiman G, Iman KL: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8: 3427-3431, 1993.
23. Doglioni C, Dei Tos AP, Laurino L et al: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to estrogen receptor status. Virchows Arch 424: 47-51, 1994.
24. Leek RD, Kaklamanis L, Pezzela F, et al. Bcl-2 in normal breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor-negative tumors and in situ cancer. Br J Cancer 69: 135-139, 1994.
25. Hellemans P, van Dam PA, Weyeler J et al: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.
26. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
27. Brem SS, MJH, Gullino PM: Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41: 239-248, 1978.
28. Page DL: Cancer risk assessment in benign breast biopsies. Hum Pathol 17: 871-874, 1989.
29. Bose S, Lesser M, Norton L, Rosen PP: Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 120: 81-85, 1996.
30. Engels K, Fox SB, Whitehouse RM et al. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181: 207-212, 1997.
31. Meyer JS: Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 7: 171-180, 1986.
32. Weider N: Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 184: 119-122, 1998.
33. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-546, 1992.
34. Tavassoli FA: Ductal carcinoma in situ: Introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 11: 140-154, 1998.
35. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S. Page DL: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 71: 67-72, 1994.
36. Hockenberry DM, Zutter M, Hickey W et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci 88: 6961-6965, 1991.
37. Siziopikou KP, Prioleau J, Schnitt S: MIB-1 proliferation index (PI) in ductal carcinoma in situ (DCIS): Relationship to bcl-2 and p53 protein. Mod Pathol 9: 25A, 1996.
38. Leonardi E, Girlando S, Serio G, et al: PCNA and Ki-67 expression in breast carcinoma: Correlations with clinical and biological variables. J Clin Pathol 45: 416-419, 1992.
39. Gasparini G, Weidner N, Belivacqua P et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466, 1994.